On October 6, shares of pharmaceutical startup MannKind Corp. plummeted 30% to $6.30, when the company predicted it wouldn't sign a partnership deal with a well-capitalized Big Pharma company until after its experimental drug is approved. Here's the twist: MannKind's experimental drug is inhaled ...
More...
Toggle signature
||||| Mentor Group Access Now! |||||
More...
Toggle signature
||||| Mentor Group Access Now! |||||